Search

Your search keyword '"Klein, Stefan"' showing total 47 results
Start Over Author "Klein, Stefan" Journal blood
47 results on '"Klein, Stefan"'

1. Hope for motherhood: pregnancy after allogeneic hematopoietic cell transplantation (a national multicenter study)

Author

Jost, Edgar, Schmid, Christoph, Baurmann, Herrad, Blau, Igor, Holderried, Tobias, Hertenstein, Bernd, Hänel, Mathias, Bornhäuser, Martin, Neidlinger, Helga, Kobbe, Guido, Winkler, Julia, Schroeder, Thomas, Bug, Gesine, Hopfer, Olaf, Finke, Jürgen, Hasenkamp, Justin, Krüger, William, Müller, Lutz, Kröger, Nikolaus, Eder, Matthias, Luft, Thomas, Hilgendorf, Inken, Ringhoffer, Mark, Stölzel, Friedrich, Scheid, Christoph, Platzbecker, Uwe, Wortmann, Friederike, Heinicke, Thomas, Wagner, Eva, Klein, Stefan, Burchert, Andreas, Tischer, Johanna, Stelljes, Matthias, Schäfer-Eckart, Kerstin, Wolff, Daniel, Junghanss, Christian, Ritter, Markus, Kaufmann, Martin, Bethge, Wolfgang, Mytilineos, Joannis, Einsel, Hermann, Sockel, Katja, Neu, Annika, Goeckenjan, Maren, Ditschkowski, Markus, Kröger, Nicolaus, Ayuk, Francis A., Stoelzel, Friedrich, Middeke, Jan Moritz, Bertz, Hartmut, Beverungen, David, von Bonin, Malte, Egger-Heidrich, Katharina, Heberling, Lisa, Trautmann-Grill, Karolin, Teipel, Raphael, Fraccaroli, Alessia, Fante, Matthias, Scheid, Christof, Holtick, Udo, Blau, Igor Wolfgang, Wulf, Gerald, Schwerdtfeger, Rainer, Kaun, Stephan, Winter, Susann, Theuser, Catrin, Beyersmann, Jan, Bornhaeuser, Martin, Schmeller, Sandra, and Schetelig, Johannes

Published
2024
Full Text
View/download PDF

2. Graft-Versus-Host Disease (GvHD) and Steroid-Refractory GvHD after Allogeneic Hematopoietic Stem Cell Transplantation: A Large Real-World EBMT-Based Epidemiology and Treatment Pattern Study

Author

Corbacioglu, Selim, primary, Mooyaart, Jarl, additional, Polge, Emmanuelle, additional, Boreland, William, additional, Lemaitre, Jessica, additional, Peczynski, Christophe, additional, van Biezen, Anja, additional, Schroeder, Thomas, additional, Sengeloev, Henrik, additional, Avenoso, Daniele, additional, Brossart, Peter, additional, Gavriilaki, Eleni, additional, Mico', Maria Caterina, additional, Martínez, Carmen, additional, Jurado Chacón, Manuel, additional, Sica, Simona, additional, Santarone, Stella, additional, Lenhoff, Stig, additional, Ladetto, Marco, additional, Pérez-Simón, Jose A., additional, Beguin, Yves, additional, Klein, Stefan, additional, Pascual, Maria Jesús, additional, Gunes, Sibel, additional, Bobirca, Catalin, additional, Penack, Olaf, additional, and Perić, Zinaida, additional

Published
2023
Full Text
View/download PDF

3. Pooled Fecal Allogenic Microbiotherapy for Refractory Gastrointestinal Acute Graft-Versus-Host Disease : Results from Early Access Program in Europe

Author

Malard, Florent, primary, Loschi, Michael, additional, Cluzeau, Thomas, additional, Legrand, Faezeh, additional, Méar, Jean-Baptiste, additional, Lhomme, Faustine, additional, Huynh, Anne, additional, Guenounou, Sarah, additional, Borel, Cécile, additional, Desmier, Déborah, additional, Moya, Niels, additional, Charbonnier, Amandine, additional, Lebon, Delphine, additional, Labussière-Wallet, Hélène, additional, Orvain, Corentin, additional, Chantepie, Sylvain, additional, Carre, Martin, additional, Camus, Vincent, additional, Couturier, Marie-Anne, additional, Cornillon, Jérôme, additional, Chevallier, Patrice, additional, Mediavilla, Clemence, additional, Ceballos, Patrice, additional, Beauvais, David, additional, Daguindau, Etienne, additional, Bilger, Karin, additional, Klein, Stefan, additional, Bruelle, Marion, additional, Plantamura, Emilie, additional, and Mohty, Mohamad, additional

Published
2023
Full Text
View/download PDF

4. Matching for the MICA-129 polymorphism is beneficial in unrelated hematopoietic stem cell transplantation

Author

Fuerst, Daniel, Neuchel, Christine, Niederwieser, Dietger, Bunjes, Donald, Gramatzki, Martin, Wagner, Eva, Wulf, Gerald, Glass, Bertram, Pfreundschuh, Michael, Einsele, Hermann, Arnold, Renate, Stuhler, Gernot, Schaefer-Eckart, Kerstin, Freitag, Sebastian, Casper, Jochen, Kaufmann, Martin, Wattad, Mohammed, Hertenstein, Bernd, Klein, Stefan, Ringhoffer, Mark, Mytilineos, Daphne, Tsamadou, Chrysanthi, Mueller, Carlheinz, Schrezenmeier, Hubert, and Mytilineos, Joannis

Published
2016
Full Text
View/download PDF

5. Venetoclax-Based Salvage Therapy Improves Outcome in Relapsed/Refractory AML Patients Eligible for Intensive Treatment: A Propensity Score Matching Analysis

Author

Unglaub, Julia N., Schlenk, Richard F., Hanoun, Maher, Reinhardt, H. Christian, Middeke, Jan Moritz, Schäfer-Eckart, Kerstin, Steffen, Björn, Krause, Stefan W., Schliemann, Christoph, Kaufmann, Martin, Hänel, Mathias, Jost, Edgar, Crysandt, Martina, Fransecky, Lars, Einsele, Hermann, Kraus, Sabrina, Niemann, Dirk, Neubauer, Andreas, Seggewiss-Bernhardt, Ruth, Scholl, Sebastian, Klein, Stefan, Schmid, Christoph, Schaich, Markus, Platzbecker, Uwe, Baldus, Claudia D., Bornhäuser, Martin, Serve, Hubert, Röllig, Christoph, Kramer, Michael, Katelari, Elena, Janssen, Maike, Pabst, Caroline, Luft, Thomas, Dreger, Peter, Müller-Tidow, Carsten, and Sauer, Tim

Subjects
Immunology, ddc:610, Cell Biology, Hematology, Biochemistry
Published
2022

6. In Patients with Relapsed/Refractory AML Sequential Conditioning and Immediate Allogeneic Stem Cell Transplantation (allo-HCT) Results in Similar Overall and Leukemia-Free Survival Compared to Intensive Remission Induction Chemotherapy Followed By Allo-HCT: Results from the Randomized Phase III ASAP Trial

Author

Stelljes, Matthias, primary, Middeke, Jan Moritz, additional, Bug, Gesine, additional, Wagner, Eva-Maria, additional, Mueller, Lutz Peter, additional, Christoph, Schmid, additional, Krause, Stefan W., additional, Bethge, Wolfgang, additional, Jost, Edgar, additional, Platzbecker, Uwe, additional, Klein, Stefan, additional, Schubert, Jörg, additional, Niederland, Judith, additional, Kaufmann, Martin, additional, Schäfer-Eckart, Kerstin, additional, Schaich, Markus, additional, Baldauf, Henning, additional, Stölzel, Friedrich, additional, Petzold, Cathleen, additional, Röllig, Christoph, additional, Alakel, Nael, additional, Steffen, Björn, additional, Hauptrock, Beate, additional, Reicherts, Christian, additional, Schliemann, Christoph, additional, Serve, Hubert, additional, Schmidt, Alexander H., additional, Bornhäuser, Martin, additional, Mikesch, Jan-Henrik, additional, and Schetelig, Johannes, additional

Published
2022
Full Text
View/download PDF

7. Registry Data Indicate a Meaningful Chance for Successful Pregnancies after Allogeneic Stem Cell Transplantation: Results from the German Stem Cell Transplant Registry (DRST)

Author

Sockel, Katja, primary, Frank, Sandra, additional, Neu, Annika, additional, Ditschkowski, Markus, additional, Hilgendorf, Inken, additional, Goeckenjan, Mareen, additional, Stoelzel, Friedrich, additional, Middeke, Jan Moritz, additional, Kröger, Nicolaus, additional, Ayuk, Francis A., additional, Eder, Matthias, additional, Bethge, Wolfgang, additional, Finke, Jürgen, additional, Bertz, Hartmut, additional, Kobbe, Guido, additional, Kaufmann, Martin, additional, Platzbecker, Uwe, additional, Beverungen, David, additional, Schmid, Christoph, additional, von Bonin, Malte, additional, Egger-Heidrich, Katharina, additional, Heberling, Lisa, additional, Trautmann-Grill, Karolin, additional, Teipel, Raphael, additional, Bug, Gesine, additional, Tischer, Johanna, additional, Fraccaroli, Alessia, additional, Holler, Barbara, additional, Wolff, Daniel, additional, Luft, Thomas, additional, Roesler, Wolf, additional, Schäfer-Eckart, Kerstin, additional, Dressler, Sabine, additional, Scheid, Christof, additional, Holtick, Udo, additional, Klein, Stefan, additional, Blau, Igor Wolfgang, additional, Burchert, Andreas, additional, Wulf, Gerald, additional, Hasenkamp, Justin, additional, Schwerdtfeger, Rainer, additional, Kaun, Stephan, additional, Wittke, Christoph, additional, Wortmann, Friederike, additional, Neidlinger, Helga, additional, Bornhaeuser, Martin, additional, Schetelig, Johannes, additional, and of the German Cooperative Transplant Study Group, on Behalf, additional

Published
2022
Full Text
View/download PDF

8. Treatment of MDS, AML and CMML Relapse after Allogeneic Blood Stem Cell Transplantation with Azacitidine, Lenalidomide and Donor Lymphocyte Infusions - Final Results of the Prospective Azalena-Trial (NCT02472691)

Author

Schroeder, Thomas, primary, Stelljes, Matthias, additional, Christopeit, Maximilian, additional, Schmidt, Eva, additional, Scheid, Christoph, additional, Mikesch, Jan-Henrik, additional, Rautenberg, Christina, additional, Jäger, Paul, additional, Drusenheimer, Nadja, additional, Holtick, Udo, additional, Klein, Stefan, additional, Trenschel, Rudolf, additional, Haas, Rainer, additional, Germing, Ulrich, additional, Kröger, Nicolaus, additional, and Kobbe, Guido, additional

Published
2021
Full Text
View/download PDF

9. Allogeneic Hematopoietic Cell Transplantation in Patients ≤ 60 Years with Intermediate-Risk Acute Myeloid Leukemia in First Remission - Results of the Randomized Etal-1 Trial-

Author

Bornhaeuser, Martin, primary, Schliemann, Christoph, additional, Schetelig, Johannes, additional, Rollig, Christoph, additional, Kramer, Michael, additional, Glass, Bertram, additional, Platzbecker, Uwe, additional, Burchert, Andreas, additional, Haenel, Mathias, additional, Mueller, Lutz Peter, additional, Klein, Stefan, additional, Bug, Gesine, additional, Beelen, Dietrich W., additional, Roesler, Wolf, additional, Schaefer-Eckart, Kerstin, additional, Schmid, Christoph, additional, Jost, Edgar, additional, Lenz, Georg, additional, Tischer, Johanna, additional, Spiekermann, Karsten, additional, Pfirrmann, Markus, additional, Serve, Hubert, additional, Stoelzel, Friedrich, additional, Alakel, Nael, additional, Ehninger, Gerhard, additional, Berdel, Wolfgang E., additional, and Stelljes, Matthias, additional

Published
2021
Full Text
View/download PDF

10. Venetoclax-Azacitidine As Salvage Therapy and Bridge to Allogeneic Cell Transplantation in Relapsed/Refractory AML Compared to Historical Data of the SAL Registry Study

Author

Unglaub, Julia M., primary, Schlenk, Richard F., additional, Hanoun, Maher, additional, Reinhardt, H. Christian, additional, Middeke, Jan Moritz, additional, Schäfer-Eckart, Kerstin, additional, Steffen, Björn, additional, Krause, Stefan W., additional, Schliemann, Christoph, additional, Kaufmann, Martin, additional, Haenel, Mathias, additional, Jost, Edgar, additional, Crysandt, Martina, additional, Fransecky, Lars, additional, Kraus, Sabrina, additional, Einsele, Hermann, additional, Niemann, Dirk, additional, Neubauer, Andreas, additional, Seggewiss-Bernhardt, Ruth, additional, Scholl, Sebastian, additional, Klein, Stefan, additional, Schmid, Christoph, additional, Schaich, Markus, additional, Platzbecker, Uwe, additional, Baldus, Claudia D., additional, Bornhäuser, Martin, additional, Serve, Hubert, additional, Rollig, Christoph, additional, Kramer, Michael, additional, Katelari, Elena, additional, Janssen, Maike, additional, Pabst, Caroline, additional, Luft, Thomas, additional, Dreger, Peter, additional, Müller-Tidow, Carsten, additional, and Sauer, Tim, additional

Published
2021
Full Text
View/download PDF

11. Donor Genetic Determinant of Thymopoiesis rs2204985 Impacts Clinical Outcome after Single HLA Mismatched HSCT

Author

Tsamadou, Chrysanthi, primary, Gowdavally, Sowmya, additional, Platzbecker, Uwe, additional, Sala, Elisa, additional, Valerius, Thomas, additional, Wulf, Gerald, additional, Wagner, Eva Maria, additional, Kroeger, Nicolaus, additional, Murawski, Niels, additional, Einsele, Hermann, additional, Schaefer-Eckart, Kerstin, additional, Freitag, Sebastian, additional, Casper, Jochen, additional, Kaufmann, Martin, additional, Dürholt, Mareike, additional, Hertenstein, Bernd, additional, Klein, Stefan, additional, Ringhoffer, Mark, additional, Neuchel, Christine, additional, Rode, Immanuel, additional, Mytilineos, Joannis, additional, Schrezenmeier, Hubert, additional, and Fürst, Daniel, additional

Published
2021
Full Text
View/download PDF

12. Characteristics and Outcome of Patients with Acute Myeloid Leukemia and Trisomy 4

Author

Kayser, Sabine, primary, Martínez-Cuadrón, David, additional, Hanoun, Maher, additional, Stölzel, Friedrich, additional, Gil, Cristina, additional, Reinhardt, H. Christian, additional, Aguiar, Eliana, additional, Schäfer-Eckart, Kerstin, additional, Bergua Burgues, Juan Miguel, additional, Steffen, Björn, additional, Bernal, Teresa, additional, Krause, Stefan W., additional, Riaza, Rosalia, additional, Schliemann, Christoph, additional, Cervera, Jose, additional, Kaufmann, Martin, additional, Torres, Laura, additional, Haenel, Mathias, additional, Acuña-Cruz, Evelyn, additional, Jost, Edgar, additional, Algarra, Jesús Lorenzo, additional, Crysandt, Martina, additional, Fransecky, Lars, additional, Cornago Navascués, Javier, additional, Kraus, Sabrina, additional, Martinez-Lopez, Joaquin, additional, Einsele, Hermann, additional, Niemann, Dirk, additional, Neubauer, Andreas, additional, Seggewiss-Bernhardt, Ruth, additional, Scholl, Sebastian, additional, Klein, Stefan, additional, Schmid, Christoph, additional, Schaich, Markus, additional, Schmidt-Hieber, Martin, additional, Ho, Anthony D., additional, Platzbecker, Uwe, additional, Baldus, Claudia D., additional, Müller-Tidow, Carsten, additional, Thiede, Christian, additional, Bornhäuser, Martin, additional, Serve, Hubert, additional, Levis, Mark, additional, Montesinos, Pau, additional, Röllig, Christoph, additional, and Schlenk, Richard F., additional

Published
2021
Full Text
View/download PDF

13. External validation of models for KIR2DS1/KIR3DL1-informed selection of hematopoietic cell donors fails

Author

Schetelig, Johannes, primary, Baldauf, Henning, primary, Heidenreich, Falk, primary, Massalski, Carolin, primary, Frank, Sandra, primary, Sauter, Jürgen, primary, Stelljes, Matthias, primary, Ayuk, Francis Ayuketang, primary, Bethge, Wolfgang A., primary, Bug, Gesine, primary, Klein, Stefan, primary, Wendler, Sarah, primary, Lange, Vinzenz, primary, de Wreede, Liesbeth C., primary, Fürst, Daniel, primary, Kobbe, Guido, primary, Ottinger, Hellmut D., primary, Beelen, Dietrich W., primary, Mytilineos, Joannis, primary, Fleischhauer, Katharina, primary, Schmidt, Alexander H., primary, and Bornhäuser, Martin, primary

Published
2020
Full Text
View/download PDF

14. Time from Diagnosis to Treatment Does Not Affect Outcome in Intensively Treated Patients with Newly Diagnosed Acute Myeloid Leukemia

Author

Röllig, Christoph, primary, Kramer, Michael, primary, Schliemann, Christoph, primary, Mikesch, Jan-Henrik, primary, Steffen, Björn, primary, Krämer, Alwin, primary, Sauer, Tim, primary, Hänel, Mathias, primary, Herbst, Regina, primary, Schäfer-Eckart, Kerstin, primary, Noppeney, Richard, primary, Jost, Edgar, primary, Brümmendorf, Tim H, primary, Krause, Stefan W, primary, Kunzmann, Volker, primary, Einsele, Hermann, primary, Scholl, Sebastian, primary, Hochhaus, Andreas, primary, Fransecky, Lars R., primary, Kaufmann, Martin, primary, Neubauer, Andreas, primary, Niemann, Dirk, primary, Schaich, Markus, primary, Frickhofen, Norbert, primary, Kiani, Alexander, primary, Heits, Frank, primary, Krümpelmann, Ulrich, primary, Kaiser, Ulrich, primary, Kullmer, Johannes, primary, Wass, Maxi, primary, Klein, Stefan, primary, Von Bonin, Malte, primary, Middeke, Jan Moritz, primary, Thiede, Christian, primary, Stoelzel, Friedrich, primary, Schetelig, Johannes, primary, Ehninger, Gerhard, primary, Baldus, Claudia D, primary, Müller-Tidow, Carsten, primary, Platzbecker, Uwe, primary, Serve, Hubert, primary, and Bornhäuser, Martin, primary

Published
2019
Full Text
View/download PDF

15. Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation with Venetoclax, Hypomethylating Agents and DLI - a Retrospective Multi Center Study

Author

Schuler, Esther, primary, Wagner-Drouet, Eva-Maria, additional, Ajib, Salem, additional, Bug, Gesine, additional, Crysandt, Martina, additional, Dressler, Sabine, additional, Hausmann, Andreas, additional, Heidenreich, Daniela, additional, Hirschbühl, Klaus, additional, Hoepting, Matthias, additional, Jost, Edgar, additional, Kaivers, Jennifer, additional, Klein, Stefan A, additional, Kordelas, Lambros, additional, Kriege, Oliver, additional, Mueller, Lutz Peter, additional, Rautenberg, Christina, additional, Schaffrath, Judith, additional, Schmid, Christoph, additional, Wolff, Daniel, additional, Bornhaeuser, Martin, additional, Schroeder, Thomas, additional, and Kobbe, Guido, additional

Published
2019
Full Text
View/download PDF

16. Hope for Motherhood: Pregnancy After Allogeneic Hematopoietic Cell Transplantation – a National Multicenter Study

Author

Sockel, Katja, Neu, Annika, Goeckenjan, Maren, Ditschkowski, Markus, Hilgendorf, Inken, Kröger, Nicolaus, Ayuk, Francis A., Stoelzel, Friedrich, Middeke, Jan Moritz, Eder, Matthias, Bethge, Wolfgang, Finke, Jürgen, Bertz, Hartmut, Kobbe, Guido, Kaufmann, Martin, Platzbecker, Uwe, Beverungen, David, Schmid, Christoph, von Bonin, Malte, Egger-Heidrich, Katharina, Heberling, Lisa, Trautmann-Grill, Karolin, Teipel, Raphael, Bug, Gesine, Tischer, Johanna, Fraccaroli, Alessia, Fante, Matthias, Wolff, Daniel, Luft, Thomas, Winkler, Julia, Schäfer-Eckart, Kerstin, Scheid, Christof, Holtick, Udo, Klein, Stefan, Blau, Igor Wolfgang, Burchert, Andreas, Wulf, Gerald, Hasenkamp, Justin, Schwerdtfeger, Rainer, Kaun, Stephan, Junghanss, Christian, Wortmann, Friederike, Winter, Susann, Neidlinger, Helga, Theuser, Catrin, Beyersmann, Jan, Bornhaeuser, Martin, Schmeller, Sandra, Schetelig, Johannes, Jost, Edgar, Schmid, Christoph, Baurmann, Herrad, Blau, Igor, Holderried, Tobias, Hertenstein, Bernd, Hänel, Mathias, Bornhäuser, Martin, Neidlinger, Helga, Kobbe, Guido, Winkler, Julia, Schroeder, Thomas, Bug, Gesine, Hopfer, Olaf, Finke, Jürgen, Hasenkamp, Justin, Krüger, William, Müller, Lutz, Kröger, Nikolaus, Eder, Matthias, Luft, Thomas, Hilgendorf, Inken, Ringhoffer, Mark, Stölzel, Friedrich, Scheid, Christoph, Platzbecker, Uwe, Wortmann, Friederike, Heinicke, Thomas, Wagner, Eva, Klein, Stefan, Burchert, Andreas, Tischer, Johanna, Stelljes, Matthias, Schäfer-Eckart, Kerstin, Wolff, Daniel, Junghanss, Christian, Ritter, Markus, Kaufmann, Martin, Bethge, Wolfgang, Mytilineos, Joannis, and Einsel, Hermann

Abstract

•Successful pregnancies are possible among female alloHCT recipients, although birth rate is more than six times lower than in the general population.•Key factors increasing the chance of motherhood were younger age at HCT, non-malignant disease, no TBI or dose <8Gy and RIC/NMA conditioning

Published
2024
Full Text
View/download PDF

17. Classification of Donor KIR-Genotype Information to Predict Outcome after Unrelated Hematopoietic Stell Cell Transplantation: The Jury Is Still out

Author

Schetelig, Johannes, primary, Baldauf, Henning, additional, Massalski, Carolin, additional, Frank, Sandra, additional, Sauter, Jürgen, additional, Stelljes, Matthias, additional, Ayuk, Francis A., additional, Gerbitz, Armin, additional, Bethge, Wolfgang, additional, Bug, Gesine, additional, Klein, Stefan A, additional, Wendler, Sarah, additional, Heidenreich, Falk, additional, Luedemann, Julia, additional, Lange, Vinzenz, additional, de Wreede, Liesbeth C., additional, Fürst, Daniel, additional, Schmidt, Alexander H., additional, Kobbe, Guido, additional, Ottinger, Hellmut Dietmar, additional, Mueller, Carlheinz, additional, Beelen, Dietrich W., additional, Mytilineos, Joannis, additional, Fleischhauer, Katharina, additional, and Bornhäuser, Martin, additional

Published
2018
Full Text
View/download PDF

18. Salvage Autologous Transplant and Lenalidomide Maintenance Versus Continuous Lenalidomide/Dexamethasone for Relapsed Multiple Myeloma: Results of the Randomized GMMG Phase III Multicenter Trial Relapse

Author

Goldschmidt, Hartmut, primary, Baertsch, Marc-A., additional, Schlenzka, Jana, additional, Becker, Natalia, additional, Christina, Habermehl, additional, Hielscher, Thomas, additional, Raab, Marc S, additional, Hillengass, Jens, additional, Müller-Tidow, Carsten, additional, Luntz, Steffen, additional, Jauch, Anna, additional, Brossart, Peter, additional, Goerner, Martin, additional, Klein, Stefan A, additional, Schmidt-Hieber, Martin, additional, Reimer, Peter, additional, Graeven, Ullrich, additional, Fenk, Roland, additional, Haenel, Mathias, additional, Martin, Hans, additional, Lindemann, Hans-Walter, additional, Scheid, Christoph, additional, Nogai, Axel, additional, Salwender, Hans Jürgen, additional, Noppeney, Richard, additional, and Weisel, Katja, additional

Published
2018
Full Text
View/download PDF

19. KIT D816 Mutated / CBF-Negative Acute Myeloid Leukemia (AML): A New Poor-Risk Subtype Associated with Systemic Mastocytosis (SM-AML)

Author

Jawhar, Mohamad, primary, Döhner, Konstanze, additional, Kreil, Sebastian, additional, Schwaab, Juliana, additional, Shoumariyeh, Khalid, additional, Meggendorfer, Manja, additional, Span, Lambert L.F., additional, Fuhrmann, Stephan, additional, Naumann, Nicole, additional, Horny, Hans-Peter, additional, Sotlar, Karl, additional, Kubuschok, Boris, additional, von Bubnoff, Nikolas, additional, Spiekermann, Karsten, additional, Heuser, Michael, additional, Metzgeroth, Georgia, additional, Fabarius, Alice, additional, Klein, Stefan A, additional, Hofmann, Wolf-Karsten, additional, Kluin-Nelemans, Hanneke, additional, Haferlach, Torsten, additional, Döhner, Hartmut, additional, Cross, Nicholas C.P., additional, Sperr, Wolfgang R., additional, Valent, Peter, additional, and Reiter, Andreas, additional

Published
2018
Full Text
View/download PDF

20. Subgroup Analyses of the Randomized GMMG Phase III Multicenter Trial Relapse Suggest Survival Benefit of Salvage Autologous Transplant Primarily in Low Risk Multiple Myeloma

Author

Baertsch, Marc-A., primary, Schlenzka, Jana, additional, Christina, Habermehl, additional, Hielscher, Thomas, additional, Raab, Marc S, additional, Hillengass, Jens, additional, Müller-Tidow, Carsten, additional, Luntz, Steffen, additional, Jauch, Anna, additional, Brossart, Peter, additional, Goerner, Martin, additional, Klein, Stefan A, additional, Schmidt-Hieber, Martin, additional, Reimer, Peter, additional, Graeven, Ullrich, additional, Fenk, Roland, additional, Haenel, Mathias, additional, Martin, Hans, additional, Lindemann, Hans-Walter, additional, Scheid, Christoph, additional, Nogai, Axel, additional, Salwender, Hans Jürgen, additional, Noppeney, Richard, additional, Weisel, Katja, additional, and Goldschmidt, Hartmut, additional

Published
2018
Full Text
View/download PDF

21. Treatment of MDS, AML and CMML Relapse after Allogeneic Blood Stem Cell Transplantation with Azacitidine, Lenalidomide and Donor Lymphocyte Infusions Results from the Second Interim Analysis of the Prospective Azalena-Trial (NCT02472691)

Author

Schroeder, Thomas Michael, primary, Rautenberg, Christina, additional, Christopeit, Max, additional, Stelljes, Matthias, additional, Schmidt, Eva, additional, Groth, Christoph, additional, Scheid, Christoph, additional, Holtick, Udo, additional, Klein, Stefan A, additional, Beelen, Dietrich W., additional, Nachtkamp, Kathrin, additional, Haas, Rainer, additional, Germing, Ulrich, additional, Kröger, Nicolaus, additional, and Kobbe, Guido, additional

Published
2018
Full Text
View/download PDF

22. Long Term Follow up and Impact of Comorbidity Prior to Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory AML - Lessons Learned from the Prospective Bridge Trial -

Author

Middeke, Jan Moritz, primary, Herbst, Regina, additional, Parmentier, Stefani Barbara, additional, Bug, Gesine, additional, Hänel, Mathias, additional, Stuhler, Gernot, additional, Schäfer-Eckart, Kerstin, additional, Rösler, Wolf, additional, Klein, Stefan A., additional, Bethge, Wolfgang, additional, Alakel, Nael, additional, Schaich, Markus, additional, Morgner, Anke, additional, Kramer, Michael, additional, Sockel, Katja, additional, von Bonin, Malte, additional, Stölzel, Friedrich, additional, Platzbecker, Uwe, additional, Röllig, Christoph, additional, Thiede, Christian, additional, Ehninger, Gerhard, additional, Bornhäuser, Martin, additional, and Schetelig, Johannes, additional

Published
2016
Full Text
View/download PDF

23. Decitabine As Salvage Therapy for Relapse of AML and MDS after Allogeneic Stem Cell Transplantation - a Retrospective Multicenter Analysis on Behalf of the German Cooperative Transplant Study Group

Author

Schroeder, Thomas, primary, Rautenberg, Christina, additional, Krüger, William Hermann, additional, Platzbecker, Uwe, additional, Bug, Gesine, additional, Juliane, Steinmann, additional, Klein, Stefan A., additional, Hopfer, Olaf, additional, Nachtkamp, Kathrin, additional, Dienst, Ariane, additional, Kondakci, Mustafa, additional, Schmidt, Pia Verena, additional, Heyn, Claudia, additional, Haas, Rainer, additional, Germing, Ulrich, additional, Bornhäuser, Martin, additional, and Kobbe, Guido, additional

Published
2016
Full Text
View/download PDF

25. Improved Safety with the Use of Subcutaneous Bortezomib in Combination with Panobinostat and Dexamethasone: Preliminary Data from a Panobinostat Global Expanded Treatment Protocol

Author

Guenther, Andreas, primary, Mügge, Lars-Olof, additional, Haenel, Mathias, additional, Schjesvold, Fredrik H., additional, Lechner, Daniel, additional, Yaser, Sameer, additional, Hebart, Holger, additional, Gisslinger, Heinz, additional, Greil, Richard, additional, Gunsilius, Eberhard, additional, Goerner, Martin, additional, Weisel, Katja, additional, Dürig, Jan, additional, Elemary, Mohamed, additional, Wolleschak, Denise, additional, Klein, Stefan A., additional, Munder, Markus, additional, Kiani, Alexander, additional, Nahi, Hareth, additional, Junghanss, Christian, additional, Campello-Iddison, Valerie, additional, Deniau, Ythier, additional, Feng, Xiaoshu, additional, and Einsele, Hermann, additional

Published
2016
Full Text
View/download PDF

26. Salvage Autologous Transplant and Lenalidomide Maintenance Versus Continuous Lenalidomide/Dexamethasone for Relapsed Multiple Myeloma: Long Term Follow up Results of the Randomized GMMG Phase III Multicenter Trial Relapse

Author

Baertsch, Marc-Andrea, Schlenzka, Jana, Hielscher, Thomas, Raab, Marc S., Sauer, Sandra, Merz, Maximilian, Mai, Elias K., Müller-Tidow, Carsten, Luntz, Steffen, Jauch, Anna, Brossart, Peter, Goerner, Martin, Klein, Stefan, Glass, Bertram, Reimer, Peter, Graeven, Ullrich, Fenk, Roland, Hänel, Mathias, von Metzler, Ivana, Hans W., Lindemann, Scheid, Christof, Nogai, Axel, Salwender, Hans, Noppeney, Richard, Besemer, Britta, Weisel, Katja, and Goldschmidt, Hartmut

Abstract

IntroductionThe randomized, controlled, multicenter, phase III GMMG ReLApsE trial compared lenalidomide/dexamethasone (Rd) re-induction, salvage high dose chemotherapy, autologous stem cell transplantation (HDCT/ASCT) and lenalidomide (R) maintenance with standard continuous Rd. We have previously reported the absence of a significant survival benefit in the primary analysis. However, landmark analyses from salvage HDCT performed due to the fact that ~30% of patients in the HDCT arm did not receive salvage HDCT/ASCT suggested a survival benefit in patients undergoing salvage HDCT/ASCT. Here we report long term follow up results from the GMMG ReLApsE trial.

Published
2023
Full Text
View/download PDF

27. Allogeneic Hematopoietic Stem Cell Transplantation in Advanced Systemic Mastocytosis

Author

Christen, Deborah, Lübke, Johannes, Kaiser, Anne, Schwaab, Juliana, Shoumariyeh, Khalid, Jentzsch, Madlen, Sockel, Katja, Schaffrath, Judith, Ayuk, Francis A., Stelljes, Matthias, Hilgendorf, Inken, Sala, Elisa, Kaivers, Jennifer, Schönland, Stefan, Wittke, Christoph, Hertenstein, Bernd, Radsak, Markus P., Kaiser, Ulrich, Brückl, Valeska, Kröger, Nicolaus, Klein, Stefan, Hofmann, Wolf-Karsten, Brümmendorf, Tim H., Jost, Edgar, Panse, Jens, and Reiter, Andreas

Abstract

Purpose

Published
2023
Full Text
View/download PDF

28. The Extent of Labile Plasma Iron (LPI) Predicts for Non-Relapse-Mortality (NRM) in AML and MDS Patients with Systemic Iron Overload Undergoing Allogenic Stem Cell Transplantation Results of the Prospective, German-Austrian Allive Trial

Author

Wermke, Martin, primary, Eckoldt, Julia, additional, Goetze, Katharina, additional, Klein, Stefan A., additional, Bug, Gesine, additional, Stölzel, Friedrich, additional, von Bonin, Malte, additional, Schetelig, Johannes, additional, Laniado, Michael, additional, Plodeck, Verena, additional, Hofmann, Wolf-Karsten, additional, Ehninger, Gerhard, additional, Bornhäuser, Martin, additional, Wolf, Dominik, additional, Theurl, Igor, additional, and Platzbecker, Uwe, additional

Published
2015
Full Text
View/download PDF

29. Influence of the Insertion Site on Central Venous Catheter Related Complications in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation, High Dose Therapy or Induction Therapy for Acute Leukemia

Author

Heidenreich, Daniela, primary, Muetzel, Eleonore, additional, Kreil, Sebastian, additional, Nolte, Florian, additional, Faust, Melanie, additional, Jawhar, Mohamad, additional, Hecht, Anna, additional, Hofmann, Wolf-Karsten, additional, and Klein, Stefan A., additional

Published
2015
Full Text
View/download PDF

30. The Multicentre, Double-Blinded, Placebo-Controlled Clinical-Trial (Pre-GvHD) for Prediction and Pre-Emptive Treatment of Acute GvHD

Author

Weissinger, Eva M, Jochen, Metzger, Schleuning, Michael, Schmid, Christoph, Messinger, Diethelm, Beutel, Gernot, Wagner, Eva-Maria, Schetelig, Johannes, Baurmann, Herrad, Rank, Andreas, Stolzl, Friedrich, Schäfer-Eckhard, Kerstin, Westphal, Karin, Bethge, Wolfgang, Bunjes, Donald w., Heidenreich, Daniela, Klein, Stefan, Wolff, Daniel, Holler, Ernst, Kreipe, Hans H, Jonigk, Danny, Türüchanow, Irina, Rothmann, Clara, Raad, Julia, Durban, Annika, Hamwi, Iyas, Ehrlich, Steve, Schweier, Patrick, Krauter, Jurgen, Stadler, Michael, and Ganser, Arnold

Published
2017
Full Text
View/download PDF

31. Haploidentical Second Allogeneic Hematopoietic Stem Cell Transplantation for the Treatment of Acute Leukemia Relapse after First Allo-HSCT: A Retrospective Registry Analysis of 60 Patients on Behalf of the German Cooperative Transplant Group

Author

Christopeit, Maximilian, primary, Tischer, Johanna, additional, Bornhäuser, Martin, additional, Uharek, Lutz, additional, Pfrepper, Christian, additional, Behre, Gerhard, additional, Niederwieser, Dietger, additional, Kröger, Nicolaus, additional, Rösler, Wolf, additional, Klein, Stefan A., additional, Beelen, Dietrich, additional, Hausmann, Andreas, additional, Bethge, Wolfgang, additional, and Schmid, Christoph, additional

Published
2014
Full Text
View/download PDF

32. – Updated Results from the Bridge Trial: Long-Term Survival and Impact of Donor Availability – Clofarabine Salvage Therapy Prior to Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory AML

Author

Middeke, Jan Moritz, primary, Herbst, Regina, additional, Parmentier, Stefani B, additional, Bug, Gesine, additional, Hänel, Mathias, additional, Stuhler, Gernot, additional, Schäfer-Eckart, Kerstin, additional, Rösler, Wolf, additional, Klein, Stefan A., additional, Bethge, Wolfgang, additional, Bitz, Ulrich, additional, Alakel, Nael, additional, Schaich, Markus, additional, Morgner, Anke, additional, Kramer, Michael, additional, Platzbecker, Uwe, additional, Röllig, Christoph, additional, Thiede, Christian, additional, Ehninger, Gerhard, additional, Bornhäuser, Martin, additional, and Schetelig, Johannes, additional

Published
2014
Full Text
View/download PDF

34. Azacitidine and Donor Lymphocyte Infusions As Treatment For Relapse After Allogeneic Stem Cell Transplantation - a Retrospective Multicenter Analysis In 115 Patients On Behalf Of The German Cooperative Transplant Study Group

Author

Schroeder, Thomas, primary, Rachlis, Elena, additional, Bug, Gesine, additional, Stelljes, Matthias, additional, Klein, Stefan A., additional, Wolf, Dominik, additional, Ringhoffer, Mark, additional, Czibere, Akos G., additional, Nachtkamp, Kathrin, additional, Dienst, Ariane, additional, Kondakci, Mustafa, additional, Stadler, Michael, additional, Platzbecker, Uwe, additional, Uharek, Lutz, additional, Luft, Thomas, additional, Fenk, Roland, additional, Germing, Ulrich, additional, Bornhäuser, Martin, additional, Kröger, Nicolaus, additional, Haas, Rainer, additional, and Kobbe, Guido, additional

Published
2013
Full Text
View/download PDF

35. Clofarabine Salvage Therapy Prior To Allogeneic Hematopoietic Stem Cell Transplantation In Patients With Relapsed Or Refractory AML – Results Of The Bridge Trial –

Author

Middeke, Jan Moritz, primary, Herbst, Regina, additional, Parmentier, Stefani, additional, Bug, Gesine, additional, Hänel, Mathias, additional, Stuhler, Gernot, additional, Schäfer-Eckart, Kerstin, additional, Rösler, Wolf, additional, Klein, Stefan A., additional, Bethge, Wolfgang A, additional, Bitz, Ulrich, additional, Alakel, Nael, additional, Schaich, Markus, additional, Morgner, Anke, additional, Pursche, Stefan, additional, Kramer, Michael, additional, Platzbecker, Uwe, additional, Röllig, Christoph, additional, Thiede, Christian, additional, Ehninger, Gerhard, additional, Bornhäuser, Martin, additional, and Schetelig, Johannes, additional

Published
2013
Full Text
View/download PDF

37. Centrosome Aberrations in Bone Marrow Cells From Patients with Myelodysplastic Syndromes Correlate with Chromosomal Instability

Author

Fabarius, Alice, primary, Giehl, Michelle, additional, Haass, Wiltrud, additional, Nowak, Verena, additional, Schumann, Christiane, additional, Nowak, Daniel, additional, Mossner, Maximilian, additional, Schulze, Torsten J, additional, Klein, Stefan A., additional, Seifarth, Wolfgang, additional, Hofmann, Wolf-Karsten, additional, and Nolte, Florian, additional

Published
2012
Full Text
View/download PDF

38. A Multicenter Retrospective Analysis on Pentostatin As Salvage Therapy of Severe Steroid Refractory Intestinal Acute Graft Versus Host Disease

Author

Klein, Stefan A., primary, Schmitt, Thomas, additional, Bug, Gesine, additional, Schetelig, Johannes, additional, Schwerdtfeger, Rainer, additional, Schaefer-Eckart, Kerstin, additional, Schmid, Christoph, additional, Wandt, Hannes, additional, Hofmann, Wolf-Karsten, additional, Bornhaeuser, Martin, additional, Martin, Hans, additional, and Dreger, Peter, additional

Published
2011
Full Text
View/download PDF

41. Monitoring of Donor Chimerism in CD34+ Peripheral Blood Progenitors Allows to Detect Minimal Residual Disease after Allogeneic Stem Cell Transplantation -Results of a Randomized Trial

Author

Bornhaeuser, Martin, primary, Oelschlaegel, Uta, primary, Bug, Gesine, primary, Platzbecker, Uwe, primary, Lutterbeck, Karin, primary, Kiehl, Michael G, primary, Schetelig, Johannes, primary, Kiani, Alexander, primary, Illmer, Thomas, primary, Schaich, Markus, primary, Theuser, Catrin, primary, Mohr, Brigitte, primary, Brendel, Cornelia, primary, Fauser, Axel A, primary, Klein, Stefan, primary, Martin, Hans, primary, Ehninger, Gerhard, primary, and Thiede, Christian, primary

Published
2008
Full Text
View/download PDF

42. Priming with Granulocyte-Colony Stimulating Factor Did Not Improve Outcome in a Randomized Study of Elderly Acute Myeloid Leukemia but Increased Induction Mortality.

Author

Bug, Gesine, primary, Koschmieder, Steffen, additional, Krauter, Juergen, additional, Wiebe, Stefanie, additional, Hannig, Carla, additional, Hofmann, Wolf-Karsten, additional, Klein, Stefan A., additional, Zander, Caroline, additional, Heit, Wolfgang, additional, Ganser, Arnold, additional, Hoelzer, Dieter, additional, and Ottmann, Oliver G., additional

Published
2006
Full Text
View/download PDF

45. KIT D816Mutated / CBF-Negative Acute Myeloid Leukemia (AML): A New Poor-Risk Subtype Associated with Systemic Mastocytosis (SM-AML)

Author

Jawhar, Mohamad, Döhner, Konstanze, Kreil, Sebastian, Schwaab, Juliana, Shoumariyeh, Khalid, Meggendorfer, Manja, Span, Lambert L.F., Fuhrmann, Stephan, Naumann, Nicole, Horny, Hans-Peter, Sotlar, Karl, Kubuschok, Boris, von Bubnoff, Nikolas, Spiekermann, Karsten, Heuser, Michael, Metzgeroth, Georgia, Fabarius, Alice, Klein, Stefan A, Hofmann, Wolf-Karsten, Kluin-Nelemans, Hanneke, Haferlach, Torsten, Döhner, Hartmut, Cross, Nicholas C.P., Sperr, Wolfgang R., Valent, Peter, and Reiter, Andreas

Abstract

Systemic mastocytosis with an associated hematologic neoplasm (SM-AHN) is the most common subtype of advanced SM (advSM), diagnosed in up to 80% of patients. The AHN is most frequently diagnosed as a myeloid neoplasm, e.g., SM-MDS/MPNu or SM-CMML. Acquired mutations in KIT(usually KITD816, KITD816mut) are detectable in >90% of patients. The basis for the SM-AHN phenotype is usually the multi-lineage involvement, e.g. monocytes, eosinophils and other non-mast cell lineages, of KITmutations. Core binding factor (CBF) positive AML (CBFposAML) represents a distinct subtype and is identified in 5-8% of all AMLs. KITmutations, most frequently KITD816mut, are detectable in up to 45% of CBFposAML patients and are associated with an adverse prognosis. There is, however, only little information on KITD816mut/CBFnegAML. We therefore evaluated a) clinical and molecular characteristics, b) response to treatment and, c) survival and prognostic factors in 40 KITD816mut/CBFnegpatients with histologically proven SM and associated AML (SM-AML), collected at 4 centers of the European Competence Network on Mastocytosis (ECNM). Molecular analyses (n=32) revealed at least one additional somatic mutation (median, n=3) apart from KITD816, most frequently SRSF2(n=12, 38%), RUNX1(n=11, 34%), TET2(n=11, 34%), ASXL1(n=10, 31%), or NPM1(n=7, 22%). At least one mutation in SRSF2, ASXL1or, RUNX1(S/A/Rpos) was identified in 21/32 (66%) patients. At diagnosis of SM-AML 21/40 (52%) patients had an aberrant karyotype. Secondary AML evolved in 29/40 (73%) patients from SM ± associated myeloid neoplasm and longitudinal molecular analyses revealed acquisition of new somatic mutations (TP53, n=2; NPM1, n=1; RUNX1, n=1, ASXL1, n=1; BCOR, n=1; IDH1/2, n=1) and/or karyotype evolution in 15/16 (94%) patients at the time of SM-AML. Thirty-one of 40 (78%) patients were treated with intensive chemotherapy (ICT) with a complete response (CR) rate of 40%. Allogeneic stem cell transplantation (SCT) was performed in 12/40 (30%) patients with durable CR in 6/12 (50%) patients. S/A/Rposand/or the presence of a poor-risk karyotype were adverse predictive markers for response to treatment. To further investigate whether KITD816mut/CBFnegAMLdefines a distinct AML subtype associated with SM, two independent AML databases (AMLdatabases) were retrospectively screened and 69 KITD816mut/CBFnegAML patients identified. The comparison between KITD816mut/CBFnegSM-AML from ECNM (n=40) centers with KITD816mut/CBFnegAMLdatabases(n=69) revealed remarkable similarities: a) a high KITD816 variant allele frequency (VAF) (median 34% vs. 29%), b) with the exception of SRSF2(38 vs. 18%), a highly similar mutation landscape, rather comparable to that of advSM (Jawhar et al., Blood 2017) than to that of de novoAML, c) in contrast to de novoAML, a low frequency of FLT3mutations (3 vs. 7%), and d) a high frequency of an aberrant karyotype (52 vs. 42%). The median overall survival (OS) of 40 KITD816mut/CBFnegSM-AML and 17 evaluable KITD816mut/CBFnegAMLdatabaseswas 5.4 (95% confidence interval, CI [1.7-9.1]) and 26.4 (95% CI [0-61.0]) (P=0.015) months, respectively (Figure 1). However, if only the patients with ICT ± allogeneic SCT were compared, median OS between the two groupswas not different (16.7 vs. 26.4 months, P=0.4). In multivariate analyses, S/A/Rposand a poor-risk karyotype remained the only independent poor-risk factors with regard to OS. These results were independent of treatment modalities. We conclude that KITD816mut/CBFnegAML is a new poor-risk subtype associated with SM (SM-AML). The remarkable clinical, genetic and prognostic similarities between SM-AML and AMLdatabasessuggest that a significant proportion of the AMLdatabasespatients may in fact have SM-AML. We therefore strongly recommend to determine serum tryptase and KITD816 mutation status in all AML patients, and to perform bone marrow histology in KITD816mutpatients. These simple diagnostic measures would allow reclassification to SM-AML and inclusion of KIT inhibitors in established treatment modalities of AML.

Published
2018
Full Text
View/download PDF

46. Systemic Mastocytosis with Associated Acute Myeloid Leukemia (SM-AML): a Poor-Risk Multi-Mutated Disease That Follows a Distinct Diagnostic Algorithm and Requires High-Dose Stem Cell-Targeting Therapy

Author

Jawhar, Mohamad, Kreil, Sebastian, Schwaab, Juliana, Shoumariyeh, Khalid, Span, Lambert L.F., Fuhrmann, Stephan, Naumann, Nicole, Nolte, Florian, Heidenreich, Daniela, Müller, Nadine Z., Horny, Hans-Peter, Sotlar, Karl, Haferlach, Torsten, Kubuschok, Boris, Spiekermann, Karsten, Heuser, Michael, Metzgeroth, Georgia, Fabarius, Alice, Klein, Stefan, Hofmann, Wolf-Karsten, Cross, Nicholas C.P., Meggendorfer, Manja, Kluin-Nelemans, Hanneke, Sperr, Wolfgang R., Valent, Peter, and Reiter, Andreas

Abstract

In systemic mastocytosis (SM), clinical phenotype, response to treatment and prognosis are influenced by the KITD816V mutation (80-90% of patients positive), additional mutations in SRSF2, ASXL1or RUNX1(S/A/Rpos) and chromosomal aberrations. In core-binding factor acute myeloid leukemias (CBF-AML), KITmutations are identified in about 30% of cases, conferring an adverse prognostic impact on survival. However, patients with AML are not routinely checked for the contemporaneous presence or absence of SM. We sought to evaluate a) clinical and molecular characteristics, b) responses to treatment and survival, and c) prognostic factors in 44 patients with SM and associated AML (SM-AML). The median age was 64 years (range 28-83), 64% were male. In the majority of patients (30/44, 68%), AML evolved a median of 24 months (range 2-153) after diagnosis of SM without (6/30, 20%) or with (24/30, 80%) an associated hematologic neoplasm (AHN) such as myelodysplastic syndrome (SM-MDS), myeloproliferative neoplasm (SM-MPN) or MDS/MPN (SM-MDS/MPN). Based on histopathology, SM was contemporaneously diagnosed with AML in 14/44 (32%) patients. At diagnosis of SM-AML, the median bone marrow infiltration by mast cells and myeloid blasts was 15% (range 5-65; ≥20% in 45% of patients) and 39% (range 20-95), respectively, and the median serum tryptase level was 92 μg/l (range 2-885; ≥150 in 39% of patients). In the majority of patients, material was available for molecular analyses and revealed the following markers at diagnosis of SM-AML: a) KITD816V in 36/41 (88%) patients, b) additional mutations by targeted next-generation sequencing (NGS, 28 myeloid gene panel) in 32/33 (97%) patients, the most frequent mutations were: RUNX1(n=12, 36%), TET2(n=11, 33%), SRSF2(n=11, 33%), ASXL1(n=9, 27%), IDH1/ 2(n=6, 18%), NPM1(n=6, 18%), BCOR(n=5, 15%), DNMT3A(n=4, 12%), and, c) an aberrant karyotype in 25/35 (71%) patients (in analogy to related myeloid neoplasms, e.g. MDS or AML, patients were classified according to their karyotype into three groups: favorable-, intermediate- and poor-risk; only 1 patient with a CBF translocation). Patients with a known history of SM were frequently S/A/Rpos(19/22, 86%) and acquisition of additional mutations (NPM1, n=2; IDH1, n=2; BCOR/ JAK2/ TP53/ PHF6/ RUNX1, n=1) or karyotype evolution at time of SM-AML was observed in 8/15 (53%) or 9/13 (69%) patients, respectively. NGS on DNA derived from CD34+ myeloid blasts of 6 KITD816V positive patients revealed the presence of KITD816V positive blasts in only 1/6 (17%) patients while additional mutations were found in blast cells of all 6 patients. Eight patients received supportive care due to age and/or comorbidity. In 36 patients, disparate combinations of AML-type chemotherapy ± hypomethylating agents (HMA) ± cladribine (n=16) were administered. Cytarabine-based consolidation treatment was administered in 4/36 (11%) patients in complete remission (CR). Allogeneic stem cell transplantation (SCT) was performed in 15/36 (42%) patients, only 6/15 (40%) patients were in CR prior to allogeneic SCT. Overall, 5/10 (50%) patients in CR of AML showed persistence of SM. From diagnosis of SM-AML, the median observation was 10 months (range 0-200); 32/44 (73%) patients died during observation. The median overall survival (OS) was 11 months (95% confidence interval [CI], 4-17) with median OS of 2 (range 0-5), 4 (range 0-12) and 74 (range 0-149) months for patient cohorts who were treated with supportive care, intensive chemotherapy/HMA and intensive chemotherapy followed by allogeneic SCT, respectively (P=0.0002). On multivariate analysis, the only independent prognostic marker for OS was favorable-risk karyotype (n=14) vs. intermediate-/poor-risk karyotype (n=21; median OS 21 vs. 7 months; HR 3.2 [1.3-7.8], P=0.007). We conclude that a) SM-AML seems to be more frequent than commonly believed, b) SM-AML should be regarded as secondary AML evolving from multimutated SM-AHN, c) KITmutations are not restricted to CBF-AML, d) progression to SM-AML is often triggered by acquisition of new mutations and/or karyotype evolution, e) SM-AML has an aggressive phenotype and a poor prognosis, f) treatment of SM-AML should include a combination of intensive chemotherapy and allogeneic SCT for eligible patients and g) the disease frequency and poor prognosis warrant routine screening of all AML cases for serum tryptase and KITD816V.

Published
2017
Full Text
View/download PDF

47. Treatment of Relapse of MDS, AML and CMML after Allogeneic Blood Stem Cell Transplantation with Azacitidine, Lenalidomide and Donor Lymphocyte Infusions - Results from the First Interim Analysis of the Azalena-Trial (NCT02472691)

Author

Schroeder, Thomas, Rautenberg, Christina, Christopeit, Max, Stelljes, Matthias, Schmidt, Eva, Klein, Stefan, Scheid, Christof, Beelen, Dietrich W, Nachtkamp, Kathrin, Haas, Rainer, Germing, Ulrich, Kröger, Nicolaus, and Kobbe, Guido

Abstract

Background:

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results